John Gillespie

 SUNY Downstate Researcher Tapped by International Team Of Genetic Researchers Investigating Wuhan Coronavirus

Epidemiologist Sergios-Orestis Kolokotronis, PhD, and scientists from Taiwan, Munich, Berkeley and Madison are examining genome data from every confirmed case of 2019-nCoV to unearth insights into viral emergence Brooklyn, NY (February 6, 2020) - Twice each day, SUNY Downstate School of Public Health evolutionary epidemiologist Sergios-Orestis Kolokotronis, PhD, joins a global group of scientists in reviewing a worldwide database of the latest genomic information about the Wuhan strain of n

Henry Ford Cardiologists Find Apple iPhone 12 Magnet Deactivates Implantable Cardiac Devices

DETROIT (February 4, 2021) – One of the newest features of the Apple iPhone 12 series of mobile devices is a strong magnet that helps align the phone on Apple’s MagSafe accessory to maximize charging – a feature that raised the curiosity of Henry Ford Heart & Vascular Institute cardiologist Gurjit Singh, M.D., and his colleagues. Dr. Singh is an expert in cardiac electrophysiology, a specialty which deals with various electrical and rhythm disorders. He is an expert in the use of devices such a

Santa receives coronavirus vaccine alongside health care workers

Please enable cookies on your web browser in order to continue. The new European data protection law requires us to inform you of the following before you use our website: We use cookies and other technologies to customize your experience, perform analytics and deliver personalized advertising on our sites, apps and newsletters and across the Internet based on your interests. By clicking “I agree” below, you consent to the use by us and our third-party partners of cookies and data gathered fro

What Factory Managers Can Teach Hospital Wards

Hospitals have been borrowing management techniques from nonmedical professionals to improve care. Now they're also hiring people from outside industries. In particular, health-care providers are seeking managers with years of factory experience to help raise the quality of hospitals as they grow larger and more difficult to run.

Virginia Mason Medical Center

Rooting Out Waste In Healthcare

FDA Clears Siemens’ New High-volume Coagulation Analyzer

Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitis

Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830, relative to placebo, in adults with moderate to severe AD with history of inadequate response to topical therapies. Based on the results of this Phase 2a study, Glenmark says it is firmly committed to advancing GBR 830 for pa

New Treatment for Fibroids Without Surgery

The first oral treatment for women with the common condition of uterine fibroids could be available as soon as summer 2018, with two other medications in the pipeline. The drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus. “For the longest time we have...

Allergan preps 300-representative army, branded DTC to make Esmya a 'flagship' women's health drug | FiercePharma

From where Allergan’s sitting, forthcoming uterine fibroid treatment Esmya could become a flagship product. But the company knows that getting it there won’t be easy—or cheap. For one, there’s going to be “a lot of education required” to make Esmya successful, company commercial chief Bill Meury said in an interview. Currently, there are no FDA-approved treatments for uterine fibroids, and Allergan’s research suggests that many women living with the condition aren’t aware of treatment options.

Pipeline of novel immunotherapies may offer ‘more nuanced approach’ to cancer treatment

Glenmark Pharmaceuticals developed bispecific engagement by antibodies based on the T-cell receptor technology, or BEAT, to attempt to overcome limitations encountered with bsAbs. “We have chosen to go into T-cell redirecting with this technology because we would be able to actually redirect and activate T cells toward the tumor by making an ‘IgG-like’ antibody that has two binding properties — a tumor antigen on the cell surface presented by the tumors and the other on the cell surface of T cells,” Kurt Stoeckli, PhD, president and chief scientific officer of Glenmark Pharmaceuticals, told HemOnc Today. “By doing so, you essentially access the body’s internal system designed by mother nature to be the surveillance for immunity.”

2e Creative acquires Indiana marketing, sales agency Fire & Rain

Spyryx Biosciences Reports Positive Data on SPX-101 at American Thoracic Society International Conference

DURHAM, N.C., May 24, 2017 /PRNewswire/ -- Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, shared positive data highlighting clinical safety and pharmacokinetics in healthy volunteers and the preclinical mechanism of action of SPX-101, the Company's pipeline therapeutic treatment for cystic fibrosis (CF), at the American Thoracic Society International Conference in Washington, DC.  Based on this positive dat

Siemens Healthcare joins CANCER-ID in search of new tools to detect and manager cancer

Siemens Healthcare has joined the CANCER-ID consortium, an initiative of the European Union's Innovative Medicines Initiative (IMI), to explore the potential of blood-based biomarkers to revolutionize the detection and treatment of cancer. This consortium currently includes 33 partners from 13 countries working together to establish standard protocols for the clinical validation of blood-based biomarkers. These biomarkers, including circulating tumor cells (CTCs), are potential indicators for the tumor burden of patients living with cancer, especially for patients for whom biopsies of the tumor are not available. Blood-based tests (also known as "Liquid Biopsies") that could detect and track CTCs would offer the convenience of a simple blood test that allows doctors to reliably monitor a patient's condition. The information provided by these simple tests may improve the range and efficacy of treatment options from which physicians and their patients could choose

Siemens and ASCP award 153 scholarships to medical laboratory students in 2015

· Agreement with Blue Earth Diagnostics Ltd. grants U.S. rights for clinical trial supply and for exclusive commercial manufacturing and distribution of PET imaging agent upon FDA approval Siemens Healthcare Diagnostics and the American Society for Clinical Pathology (ASCP) have awarded a combined $155,000 in scholarships to the nation’s top undergraduate and graduate medical laboratory students for the 2014 – 2015 academic year [> see Winners]. Since 2003, more than $1.6 million in scholarship

New Jersey Acting Governor Kim Guadagno Joins Siemens to Unveil Major Expansion and Renovation of Healthcare Diagnostics Facility in Flanders

New Jersey Acting Governor Kim Guadagno today joined Siemens Healthcare Diagnostics and Siemens Real Estate (SRE) to unveil an expanded state-of-the-art production facility and new open-plan workspace at Siemens’ Flanders, New Jersey site. Acting Governor Guadagno participated in the ribbon-cutting ceremony along with key Siemens executives including: Franz Walt, CEO, Chemistry, Immunoassay, Automation and Diagnostics IT Business Unit, Siemens Healthcare Diagnostics; Jerome Hagedorn, Site Head,